Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Executives On The Move: Santhera Pharmaceuticals Announces Its Next CEO And Checkmate And Imago Bring Aboard Business Leaders

Executive Summary

Santhera Pharmaceuticals, developer of treatments for neuromuscular and pulmonary conditions, announces its next CEO, and cancer immunotherapy firm Checkmate Pharmaceuticals and neoplastic myeloid disease company Imago BioSciences each add a CBO.

You may also be interested in...



Execs On The Move, June 2020

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Executives On The Move: Boehringer Announces US Promotion, Immatics Chooses A CMO And DalCor Pharma Fills C-Suite Commercial Post

Boehringer Ingelheim announces its BI Pharma president to take helm from retiring US country managing director and chief executive officer. Immunotherapeutics developer Immatics Biotechnologies chooses GSK cell therapy head as CMO, and precision medicine firm DalCor Pharmaceuticals picks a chief commercial officer.

Executives On The Move: Clinical Positions Filled At Gilead, Sanifit and Spectrum, And Ferring Pharma US Officer Is Promoted

Anti-viral pharma Gilead Sciences, vascular calcification treatment firm Sanifit and hematology and oncology drug developer Spectrum Pharmaceuticals each select a new VP, clinical development. Also, to oversee its group in the US, multinational Ferring Pharmaceuticals promotes its US chief commercial officer to president.

Topics

UsernamePublicRestriction

Register

LL1122620

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel